3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Emily Reiser of Texas Medical Center Innovation, Atul Varadhachary of Fannin Innovation Studio, and Vicki Knott of Crux OCM. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to two local innovators, as well as one honorary Houstonian, across industries — energy, health care, and more — recently making headlines in Houston innovation.

Emily Reiser, senior manager for innovation community and engagement for Texas Medical Center Innovation

Emily Reiser joins the Houston Innovators Podcast to discuss the latest at TMC Innovation. Photo courtesy of TMC Innovation

Over her past few years at Texas Medical Center Innovation, Emily Reiser has worked with over 1,000 startups. So, it's safe to say she knows what a good pitch looks like and what health tech startups need as far a support from mentors and experts goes.

She shares some of her advice and observations on this week's episode of the Houston Innovators Podcast. She also explains how TMC Innovation is uniquely positioned to advance the best and brightest in life science innovation.

"When we think about how a startup is going to be successful, we think about how they are going to build new partnerships. But we also think about all the people they're going to need to activate and bring them to the next level," Reiser says. "What we do is curate a community of high-value resources that can help these companies elevate to that next level." Click here to read more.

Atul Varadhachary, managing partner of Houston's Fannin Innovation Studio

Atul Varadhachary, managing partner of Fannin Innovation Studio, says that now is the time to invest in life sciences. Photo via fannininnovation.com

Fannin Innovation Studio is hard at work finding, supporting, and accelerating life science innovations, but, according to Managing Partner Atul Varadhachary, the organization can be doing so much more — if only the budget allowed.

Varadhachary makes a case for tripling or even quadrupling the number of participants in Fannin's federally accredited fellowship program. He says this one relatively small investment could push Houston closer to Boston in the life sciences stratosphere.

"I can think of nothing that could give a bigger return on investment for the city," Varadhachary says of expanding Fannin's fellowship program. Click here to read more.

Vicki Knott, co-founder and CEO of Crux OCM

A Canadian software company is expanding its presence in Houston to meet the needs of its clients. Photo courtesy of Crux OCM

For six months of the year, Vicki Knott plans to take up residence in Houston. As the co-founder and CEO of Calgary-based Crux OCM, Knott saw a big opportunity to expand her control room operations automation software business — especially when she nabbed Houston-based Phillips 66 as a client.

Calgary and Houston have a lot in common, Knott says, and she sees a very natural connection to the two regions. Knott plans to work six months of the year in Houston with the local office.

"A lot of the companies that head offices in Houston, they have head offices in Calgary," she says. "If a startup in Houston is getting traction, I think there's a natural movement to start in the Calgary market and vice versa." Click here to read more.

A Canadian software company is expanding its presence in Houston to meet the needs of its clients. Photo via Getty Images

Exclusive: Canadian energy software company plans to grow local team and open Houston office

new to Hou

One of the biggest obstacles heavy industry tech startups face — especially in oil and gas — is getting that first big customer, says Vicki Knott, co-founder and CEO of Crux OCM.

"Our biggest challenge is nobody wants to be first in energy," she tells InnovationMap.

But Crux OCM, based in Calgary, overcame that challenge and currently counts Houston-based Phillips 66 among its clients. The two companies announced a pilot program for Crux OCM's pipeBOT technology earlier this year.

Crux OCM's technology focuses on automating the control room operations — something that, like most automation software, increases revenue and reduces errors. The company, which was founded in 2017, also allows its clients consistency and reliability with its software.

"Even though the pumps and the equipment are automated, control room operators are still executing procedures, checklist, and rules of thumb on their own via screens," Knott says. "If you think of pilots and planes have autopilot software, why don't our control room operators? That's really the problem we set out to tackle."

Vicki Knott is co-founder and CEO of Crux OCM. Photo courtesy

Automation is certainly a growing opportunity for energy companies — especially in light of the pandemic that forced remote work and less on-site personnel across industries. Knott says just over a year ago, Crux OCM saw increased interest.

"We had a couple customers who had their capital budget cut when the pandemic hit and when oil went negative, and we had a couple customers who said they were doubling down on software like this," Knott explains.

The company has raised $3 million in venture funding, backed by Root Ventures, Angular Ventures, and Golden Ventures. Knott says another funding round is on the horizon as is growth for its Houston presence.

Crux OCM currently has three full-time Houston employees and is looking to grow that team in the next six months. Specifically, the local team will focus on sales, as well as product development, as the company's head of sales and senior product manager are both based here. As the local clientbase grows, Knott says they will also need to hire deployment engineers as well.

A new office to support this growing team is also in the works. Knott says she's looking for space in North Houston, and, depending on how comfortable people are returning to offices and meetings, it could open as early as later this year.

Calgary and Houston have a lot in common, Knott says, and she sees a very natural connection to the two regions. Knott plans to work six months of the year in Houston with the local office.

"A lot of the companies that head offices in Houston, they have head offices in Calgary," she says. "If a startup in Houston is getting traction, I think there's a natural movement to start in the Calgary market and vice versa."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings